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Abstract
Background: The association between hormone treatment (HT) and mortality remains controversial. This study aimed to
determine whether the risk of mortality associated with HT use varies depending on the specific characteristics of treatment
and genetic variability in terms of the estrogen receptor.
Methodology/Principal Findings: A prospective, population-based study of 5135 women aged 65 years and older who
were recruited from three cities in France and followed over six years. Detailed information related to HT use was obtained
and five estrogen receptor polymorphisms were genotyped. The total follow-up was 25,436 person-years and during this
time 352 women died. Cancer (36.4%) and cardiovascular disease (19.3%) were the major causes of death. Cox proportional
hazards models adjusted for age, education, centre, living situation, comorbidity, depression, physical and mental
incapacities, indicated no significant association between HT and mortality, regardless of the type or duration of treatment,
or the age at initiation. However, the association between HT and all-cause or cancer-related mortality varied across women,
with significant interactions identified with three estrogen receptor polymorphisms (p-values=0.004 to 0.03) in adjusted
analyses. Women carrying the C allele of ESR1 rs2234693 had a decreased risk of all-cause mortality with HT (HR: 0.42, 95% CI:
0.18–0.97), while in stark contrast, those homozygous for the T allele had a significantly increased risk of cancer-related
mortality (HR: 3.18, 95% CI: 1.23–8.20). The findings were similar for ESR1 rs9340799 and ESR2 rs1271572.
Conclusions/Significance: The risk of mortality was not associated with HT duration, type or age at initiation. It was
however not equal across all women, with some women appearing genetically more vulnerable to the effects of HT in terms
of their estrogen receptor genotype. These findings, if confirmed in another independent study, may help explain the
differential susceptibility of women to the beneficial or adverse effects of HT.
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Introduction
Hormone treatment (HT) remains the treatment of choice for
alleviating menopause-related symptoms which affect up to 80%
of women in Western countries [1] and improving their health-
related quality of life [2]. Weighing up the risks to benefits
associated with the use of HT however, remains an important yet
complex issue. It is known to reduce the risk of osteoporosis and
fractures [3], but increases the risk of venous thromboembolism
[4] and breast cancer [3]. Whether or not HT can modify the risk
of mortality remains controversial. Although the majority of
observational studies indicate that HT is beneficial [5,6,7,8],
reducing coronary heart disease risk and cardiovascular-related
deaths [9,10,11], this has not been supported by the predominantly
non-significant findings from large randomized controlled trials
(RCTs) [12,13,14,15,16]. The Women’s Health Initiative Study
actually found that conjugated equine estrogen (CEE) with
medroxyprogesterone acetate (MPA) increased the risk of CV disease
[15], although this was limited to the oldest group of women [17] and
there was no significant increased risk of mortality. While the nature
of a RCT enables the ‘‘healthy HT-user’’ bias to be minimized, the
majority of RCTs have involved older postmenopausal women who
were administered a specific form of oral synthetic treatment (CEE
with or without MPA) over a relatively short duration [12,14,15].
Otherformsof treatmentgiven fordifferentperiods of time mayhave
more beneficial effects on health-outcomes and survival. This could
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34112include natural estrogen-progestagen preparations composed of
estradiol with or without progesterone [18,19], transdermal rather
than oral administration [4] and longer periods of treatment [6,9,20].
In addition, women participating in observational studies represent
the ‘‘usual’’ clinical situation, where treatment is generally sought for
the relief of menopausal-symptoms at a younger age. Increasing
evidence suggests there is a ‘‘critical window period’’, whereby
initiating HT around the menopause but not later in life could
specifically reduce coronary heart disease and overall mortality (see
for review [21,22]), although this has seldom been tested.
It is also possible that some women are genetically more
susceptible to the effects of HT than others [23,24,25], which may
help explain inconsistencies in the literature. The actions of
estrogen occur in large part through intracellular activation of its
two principal receptors (ESR1 and ESR2), and allelic variants in
the genes encoding these receptors could influence HT-mediated
signal transduction [26]. The intracellular concentration of these
receptors appears to be correlated to the cellular response to
estrogens [27]. Polymorphisms of these receptors have been shown
to modify the effect of HT on high-density-lipoprotein cholesterol
[28] and breast cancer [23], but whether this can influence
survival has not yet been examined.
This study investigated the association between HT and
mortality by examining characteristics of HT, in particular the
duration and type of treatment, and the period when treatment
was first initiated. Estrogen receptor polymorphisms which could
modify estrogen signalling were also examined to determine
whether genetic variability may help explain different susceptibility
to the effects of HT on mortality.
Materials and Methods
Ethics Statement
The study protocol was approved by the Ethical Committee of
the University Hospital of Kremlin-Bice ˆtre (France) and written
informed consent was obtained from all participants.
Participants
The Three-City Study (3C) is a multi-centre prospective cohort
study involving the French cities of Bordeaux, Dijon and
Montpellier [29]. Eligible participants (aged at least 65 years
and non-institutionalised) were recruited by random selection from
the electoral rolls between 1999 and 2001. Three follow-up
examinations were performed at 2, 4 and 6 years. Participants
were administered standardised questionnaires by trained staff and
underwent a number of clinical examinations.
Of the 5524 women initially recruited in the 3C Study who
were not diagnosed with probable or possible dementia, eight
participants were lost to follow-up, 219 women were missing data
on HT use and 162 had incomplete data concerning the
covariates. A sub-sample of 4463 women from the 5135 remaining
had complete genotyping data. Compared to the analysed sample,
participants not included in this analysis were more likely to be
older, have a lower education level, physical incapacities, cognitive
impairment, depressive symptoms (p-values,0.001) and comor-
bidity (p=0.02). They were also more likely to have died during
the follow-up period (p,0.001), but there was no significant
difference in terms of HT use or estrogen receptor genotypes.
Mortality
The exact date when participants died was obtained from death
registries. The causes of death were defined based on medical
records and interviews with the general practitioner and family
members [30]. The principal cause of death was considered in this
analysis and was coded according to the tenth revision of the
International Classification of Diseases (ICD-10) as follows: cancer
(ICD-10: C00-D48), circulatory disease which includes cardiovas-
cular disease and stroke (ICD-10: I00-I99, R960), respiratory and
infectious disease (ICD10: J00-J99), cachexia and diseases of the
digestive tract (ICD-10: R64, K00-K93) and ill-defined causes
(ICD-10: remaining R00-R99).
Hormone treatment
Participants recorded current and past use of HT at inclusion
and detailed information related to the treatment. Treatment use
was validated by presentation of the prescription or the medication
itself. Current users were classified according to the route of
estrogen administration and the type of progestogen (progesterone
or progestins). The duration of current HT and the timing of
initiation of first treatment in relation to the menopause were also
examined, with age at menopause being defined as one year
without menses.
Estrogen receptor polymorphisms
Fasting venous blood samples were taken from the participants
at baseline. DNA was extracted from white blood cells (Puregene
kit, Qiagen, France) and stored at 280uC. Genotyping was
performed by Kbiosciences (Hoddesdon Herts, UK) using their
competitive allele-specific PCR Single-Nucleotide Polymorphism
(SNP) genotyping system (KASPar). The amplified PCR products
were analysed by fluorescence scanning in a BMG labtech
Pherastar scanner and the results were interpreted with their
KlusterCaller 1.1 software. The error rate for the KASPar assay
system is less than 0.3%.
The two most commonly studied ESR1 polymorphisms were
examined [24,31,32,33], rs2234693 and rs9340799 (otherwise
known as PvuII and XbaI), which are located at position 397 and
351 of intron 1 respectively, and they appear to be functionally
significant [34,35]. Three ESR2 polymorphisms with unknown
functional consequences but showing potential causal associations
with other hormone-related health outcomes [25,36] were
investigated: rs1256049 (position 1082 of exon 5), rs4986938
(position 1730 in the 39-untranslated region of exon 8) and
rs1271572 in the promoter region.
Covariates
Information was gathered at baseline on the participant’s age,
educationlevel,livingsituation,consumptionofalcoholandsmoking
status. Body mass index (BMI) was calculated as weight (kg) divided
by the height squared (m
2). The Centre for Epidemiology Studies
Depression Scale (CES-D) [37] was used for the assessment of
depressive symptoms (CES-D $16). Participants were classified as
having physicalactivity limitations iftheywere unableto completeat
least two tasks from either the Instrumental Activities of Daily Living
(IADL) or the Activities of Daily Living (ADL) scales [38]. Cognitive
function was assessed using the Mini-Mental State Examination
(MMSE) [39] and participants scoring less than 26 were classified as
cognitively impaired. Information on the health of the participants
was obtained through detailed medical questionnaires, a complete
inventory of drug use inthe preceding month and from fasting blood
samples. Participants were classified as having comorbidity if they
suffered from one or more of the following chronic illnesses: vascular
diseases (angina pectoris, myocardial infarction, stroke, cardiovas-
cular surgery, bradycardia or palpitations), asthma, diabetes (fasting
glucose$7.0 mmol/l or reported treatment), hypercholesterolemia
(total cholesterol $6.2 mmol/l),hypertension(restingblood pressure
$160/95 mm Hg or treated) or thyroid problems.
Hormone Treatment and Mortality Risk
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e34112Statistical Analysis
Chi-squared tests compared the baseline characteristics of
women according to their use of HT, as well as the characteristics
of women who had died during the follow-up period and those
who were still alive. Cox Proportional Hazard analysis modelled
the risk of mortality during the follow-up period that was
associated with HT use at baseline. The time scale used in the
Cox Model was the age of participants at inclusion, which allowed
us to account for the fact that the risk of mortality with age among
the elderly is non-proportional, and Cox models with delayed
entry were used [40]. Multivariate analysis also controlled for
covariates which were significantly associated with mortality and
which could potentially confound the relationship between
mortality and HT use, including education, living situation,
physical incapacities, cognitive impairment, depressive symptoms
and comorbidity.
Chi-squared tests were used to compare the distribution of
estrogen receptor genotypes with those predicted under the
Hardy-Weinberg equilibrium and pair-wise linkage disequilibrium
was estimated. Assuming a dominant model, comparing the
dominant allele with the combined group of heterozygotes and
homozygotes for the variant allele, a first-order interaction
between the polymorphisms and current HT was examined by
including a product term in the multivariate Cox models. This was
based on our a priori hypothesis that estrogen receptor polymor-
phisms could moderate the effect of estrogen on mortality. When
significant interactions were found, subsequent analysis was
stratified by genotype to determine independent group effects.
There was no indication of colinerality between the covariates in
the adjusted models. SAS version 9.1 (SAS Institute, Inc., Cary,
North Carolina) was used for all of the statistical analysis.
Results
Study population
The women in this study were aged from 65 to 100 years.
Almost 14% were current users of HT and a slightly higher
percentage (16.5%) reported past use (Table 1). Current HT users
were younger and better educated compared with both past and
never users and they were less likely to have physical activity
limitations or comorbidity.
The total follow-up time for the study was 25,436 person-years,
over a median 5.2 years (interquartile range 4.6–5.7 years) and
during this period 352 women (6.9%) died. The majority of
women died from causes related to cancer (36.4%) or circulatory
disease (19.3%), including cardiovascular disease and stroke. A
substantial number died from ill-defined causes (23.3%), as the
result of multiple pathologies and frailty. Mortality was signifi-
cantly associated with a number of the health related variables
examined (Table 2), and women who died during follow-up were
also older, less educated and more likely to live alone. In
unadjusted chi-squared analysis (Table 3), women who reported
the use of current treatment were less likely to die (2.2%),
compared with past (6.2%) or never HT users (8.0%) (p,0.001).
Current HT users were more likely to die of cancer but were less
likely to die of cardiovascular disease, compared to past and never
user. In the latter case only, this difference was significant.
Association between hormone treatment and mortality
Adjusted analysis using Cox proportional hazards models,
showed no significant difference in the risk of all-cause mortality
between never, past and current HT users (Table 4). These
differences also remained non-significant after additional adjust-
ment for age at menopause. Examining further the characteristics
of current HT, no significant difference in mortality risk was found
based on the duration or type of treatment used or between
women who started treatment close to the menopause versus those
who initiated HT more than five years later. In terms of cancer-
related death, neither current nor past HT users had a significantly
modified risk of death compared to never users (past HT: multi-
adjusted HR=1.30, 95% CI: 0.82–2.07; current HT: multi-
adjusted HR=1.13, 95% CI: 0.59–2.15). No other cause-specific
death could be investigated as the numbers were too small. In
Table 1. Baseline characteristics of the 5135 female participants according to their use of hormone treatment.
Baseline Characteristic
Current HT
(n=714)
Past HT
(n=845)
Never
(n=3576) Statistic (df) p
Mean (S.D.) f
Age (years) 70.3 (3.4) 73.2 (5.0) 75.2 (5.6) 280.9 ,0.001
BMI (kg/m
2) 24.3 (3.5) 25.2 (4.1) 25.5 (4.5) 23.9 ,0.001
% x
2
$12 years of education 34.5 22.7 21.2 59.0 (1) ,0.001
Married or living with others 62.9 54.7 47.5 62.3 (1) ,0.001
High alcohol consumption ($24 g per day) 5.0 4.2 4.0 1.4 (1) 0.51
Heavy smoker ($10 pack years) 4.1 3.7 3.9 0.2 (1) 0.92
Physical activity limitations 4.0 9.2 12.2 44.7 (1) ,0.001
Comorbidity 36.6 45.7 49.0 37.3 (1) ,0.001
Cognitive impairment (MMSE ,26) 5.9 7.1 6.8 1.0 (1) 0.61
Depressive symptoms (CES-D $16) 28.0 31.0 28.9 1.9 (1) 0.38
Centre 37.4 (2) ,0.001
Bordeaux 15.6 21.0 25.0
Dijon 60.2 52.3 52.3
Montpellier 24.2 26.8 22.7
doi:10.1371/journal.pone.0034112.t001
Hormone Treatment and Mortality Risk
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current HT users that was observed in unadjusted analysis could
not be examined further. When all non-cancer related deaths were
examined together however, current HT use versus never use was
associated with a significantly reduced risk of mortality (multi-
adjusted HR=0.30, 95% CI: 0.11–0.83, p=0.019). Past use
of HT was not associated with a significantly modified risk of
non-cancer related deaths (multi-adjusted HR=0.89, 95% CI:
0.60–1.32).
Estrogen receptor polymorphism interactions
The estrogen receptor genotype frequencies for rs2234693 were
TT=1351, CT=2247, CC=865; for rs9340799 AA=1870,
GA=2082, GG=511; for rs1271572 GG=1434, TG=2262,
TT=767; for rs4986938 GG=1623, GA=2182, AA=658; and
for rs1256049 GG=4097, GA=361, AA=5. These frequencies
were not significantly different from those predicted by the Hardy-
Weinberg equilibrium, except in the case of the rs1271572
(x
2
1=6.1, p=0.014). The ESR1 SNPs were in strong linkage
disequilibrium (|D9|=0.98), as were the three ESR2 SNPs
(|D9|.0.90 for all pairwise comparisons). To maximise the power
of the analyses when examining the potential modifying effects of
these polymorphisms on the association between current HT and
mortality, homozygotes for the variant allele (the smallest group in
each case) were combined with the heterozygotes. Statistically
significant interactions at the 5% significance level were found
between current HT and three of the five SNPs on all-cause and
cancer-related mortality (Table 5). One of these interactions would
remain significant even if a Bonferroni correction for multiple
comparisons was applied, lowering the significance threshold to
0.005 (five SNPs and two outcomes). Such a correction would,
however, be overly conservative given that these tests for a
HT6SNP interaction were not independent (i.e. the SNPs are in
strong linkage disequilibrium and cancer-related deaths are
included within all-cause deaths). The results of the analysis
stratified by genotype are given in Table 5, to determine the
separate associations between current HT and mortality risk.
Women using HT with a C allele of ESR1 rs2234693 had a 60%
decreased risk of all-cause mortality compared to non-current
users and there was a similar trend for women with the G allele of
ESR1 rs9340799. Women with the T allele for ESR2 rs1271572
also had an almost 60% reduced risk of dying with current HT. In
contrast to the findings for all-cause mortality however, current
HT was found to greatly increase the risk of cancer-specific
Table 2. Baseline characteristics of the 5135 female participants according to their mortality status at follow-up.
Baseline Characteristic Alive (n=4783) Died (n=352) Statistic (df) p
Mean (S.D.) t
Age (years) 73.9 (5.3) 78.6 (6.4) 215.7 ,0.001
BMI (kg/m
2) 25.3 (4.3) 25.8 (4.9) 0.25 0.80
% x
2
$12 years of education 23.7 17.9 6.1 (1) 0.01
Married or living with others 51.4 42.1 11.7 (1) 0.006
High alcohol consumption ($24 g per day) 4.1 2.3 3.3 (1) 0.07
Heavy smoker ($10 pack years) 3.9 3.1 0.6 (1) 0.45
Physical activity limitations 9.0 31.0 167 (1) ,0.001
Comorbidity 45.7 59.9 26.6 (1) ,0.001
Cognitive impairment (MMSE ,26) 6.5 9.2 4.0 (1) 0.05
Depressive symptoms (CES-D $16) 28.5 38.7 16.5 (1) ,0.001
Centre 5.6 (2) 0.06
Bordeaux 22.9 25.8
Dijon 53.2 55.9
Montpellier 23.9 18.3
doi:10.1371/journal.pone.0034112.t002
Table 3. Cause of death according to the use of hormone treatment at baseline.
Hormone
Therapy All-cause Cancer
Cardiovascular
disease
Respiratory,
infectious disease
Cachexia, diseases of
the digestive tract
Other
causes Ill-defined
%( n ) % % % % %
Never 8.0 (284) 32.8 24.3 8.5 4.2 9.1 21.1
Past HT use 6.2 (52) 44.2 17.3 7.7 5.8 5.8 19.2
Current HT use 2.2 (16) 75.0 6.3 12.5 0 0 6.2
p-value
a ,0.001 0.32 ,0.001 0.30 0.41 0.04 0.005
aUnadjusted chi-squared analysis for the difference in the frequency of deaths according to HT use.
doi:10.1371/journal.pone.0034112.t003
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and rs9340799, respectively, and for those with the GG genotype of
ESR2 rs1271572.
Discussion
We have investigated the association between HT and mortality,
focusing on characteristics of treatment and the potentially
modifying effect of estrogen receptor polymorphisms. While we
found no significant association between HT and all-cause or
cancer-related mortality, regardless of the type of treatment,
duration of use or age at first initiation, there was some evidence
that HT may reduce the risk of non-cancer related deaths.
Furthermore, our research suggests that the association between
HT and mortality may vary depending on a woman’s genetic
profile. Further confirmation of this novel finding is required in
another independent population based study.
Comparison with other studies
The results of RCTs support the findings of our study in that they
report no effect of HT on overall mortality [12,13,14,15,16,41] or
deaths related to all types of cancers [12,14,15,16]. By contrast, the
majority of observational studies have found that HT is associated
with a decreased overall mortality risk [5,6,7,8,11] with mixed
Table 4. Cox proportional hazard models for the risk of all-cause deaths according to the use of hormone treatment at baseline.
Women Deaths Follow-up, Hazard Ratio (95% CI), p
Hormone treatment N N Person-Years Age-adjusted Multivariate adjusted
a
Never 3576 284 17,568 1 (Referent) 1 (Referent)
Past 845 52 4223 1.04 (0.77–1.41), 0.78 1.04 (0.72–1.41), 0.79
Current 714 16 3645 0.62 (0.37–1.05), 0.07 0.66 (0.39–1.12), 0.12
Characteristics of current users
b
#10 years current use 274 5 1414 0.36 (0.11–1.13), 0.08 0.37 (0.12–1.16), 0.09
.10 years current use 389 10 1970 0.74 (0.42–1.33), 0.31 0.81 (0.45–1.46), 0.49
initiated #5 yrs after menopause 385 7 1961 0.57 (0.26–1.22), 0.15 0.62 (0.29–1.34), 0.23
initiated .5 yrs after menopause 275 8 1418 0.75 (0.37–1.54), 0.44 0.77 (0.38–1.58), 0.48
unopposed estradiol HT
c 127 5 656 0.95 (0.39–2.32), 0.91 0.94 (0.39–2.30), 0.90
oral estradiol+progestagen HT 121 3 609 0.74 (0.23–2.33), 0.60 0.84 (0.26–2.65), 0.76
transdermal estradiol+progestagen HT
d 439 7 2244 0.45 (0.21–0.96), 0.04 0.48 (0.22–1.04), 0.06
aAdjusted for age, education, recruitment centre, living situation, incapacities, comorbidity, depressive symptoms and cognitive impairment.
bWith reference to never users.
c113 (89%) used transdermal estradiol treatment and 14 (11%) oral estradiol.
dThe 27 women who currently used other types of HT were not included in this analysis;
doi:10.1371/journal.pone.0034112.t004
Table 5. Cox proportional hazard models
a for the risk of dying associated with the use of current hormone treatment (versus non-
current use) at baseline, stratified by estrogen receptor genotype.
Multivariate-adjusted
b risk of mortality associated with current HT
Genotype All-cause Cancer-related
Deaths HR (95% CI) p Deaths HR (95% CI) p
ESR1 rs2234693
Interaction term 0.006 0.004
TT (n=1351) 85 1.65 (0.77–3.55) 0.20 32 3.18 (1.23–8.20) 0.017
CC/CT (n=3112) 196 0.42 (0.18–0.97) 0.042 70 0.38 (0.12–1.27) 0.12
ESR1 rs9340799
Interaction term 0.030 0.006
AA (n=1870) 115 1.39 (0.68–2.82) 0.37 41 2.43 (1.04–5.70) 0.040
GG/GA (n=2593) 166 0.42 (0.17–1.04) 0.059 61 0.31 (0.07–1.32) 0.31
ESR2 rs1271572
Interaction term 0.060 0.019
GG (n=1434) 93 1.59 (0.76–3.35) 0.22 37 2.90 (1.20–7.03) 0.018
TT/TG (n=3029) 188 0.43 (0.19–0.99) 0.049 65 0.40 (0.12–1.32) 0.13
aThis analysis was carried out on a sub-population of 4463 women for whom genotyping data was available.
bAdjusted for age, education, living status, recruitment centre, incapacities, comorbidity, depressive symptoms and cognitive impairment.
doi:10.1371/journal.pone.0034112.t005
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due to the healthy-users bias of women in observational studies who
selectively take HT and are known to be more highly educated and
with better overall health. Current HT users appeared less likely to
die (all-causes) in our study compared to never users, however after
adjustment for a number of health and lifestyle covariates, this
association was not significant. However, it cannot be excluded that
our non-significant association between HT and all-cause mortality
was related to the length of follow-up and/or the small number of
deaths. The observational studies which have examined specific
causes of death have predominately found that the reduction in
mortalitywithHTusewasduetoalargedecrease incardiovascular-
related deaths [5,8,11]. As only one woman using HT died from a
cardiovascular cause in our study, we could not perform adjusted
analysis on this specific outcome, however there was a much higher
percentage of cardiovascular deaths among women who had never
used HT, which supports previous data from observational studies
[5,6,7,8,11]. This is also supported by our finding of a 70% reduced
risk of non-cancer-related deaths for HT users.
We found no significant difference in mortality risk when we
examined the women currently using HT according to their type
or duration of treatment, or the age when they first initiated
treatment. Findings from both observational studies and RCTs
indicate that HT initiated around the menopause only may lower
the risk of cardiovascular disease [22], but such early initiation
may increase the risk of breast [42] and overall cancers [43]. Thus
the benefits of early initiation in terms of some health outcomes
may be balanced out by the negative effects on others.
Genetic variability
A novel finding of this study is the significant interaction between
HT and three of the five estrogen receptor polymorphisms
examined, such that the association between HT and mortality
varied according to women’s genetic vulnerability. Women with at
least one C or G allele, for the ESR1 rs2234693 and rs9340799
respectively, had a significantly decreased risk of dying from all
causes with current HT, while those homozygous TT or AA had a
significantly increased risk of cancer-related death with HT.
Likewise, women currently using HT who were homozygous GG
for ESR2 rs1271572 had an increased risk of death due to cancer,
while those with a T allele had a reduced risk of all-cause death.
Although we could not examine the interaction between HT and
estrogen receptor polymorphisms on cardiovascular-related mor-
tality specifically, this was the second most frequent cause of death
after cancer. Therefore, it is possible that the reduced risk of all-
cause mortality with HT for these specific genotypes, results in part
from a reduction in cardiovascular-related deaths.
The biological actions of estrogen occur in large part through
binding and intracellular activation of its two receptors, ESR1 and
ESR2 [44], which can then regulate the expression of hundred of
genes. Polymorphisms in the ERs could therefore influence
estrogen-mediated signaling by modifying the biological potency
of estrogen and thus the effect of estrogen-containing HT on
health outcomes. Indeed, the rs2234693 and rs9340799 polymor-
phisms appear to be functionally significant, with the C and G
alleles respectively being associated with higher gene expression
[34,35], and more favourable estrogen-dependent outcomes (e.g.
bone mineral density [31]). The functional consequence of the
rs1256049 has not been established and it may be in linkage
disequilibrium with other unidentified polymorphisms. To our
knowledge, no previous study has investigated whether genetic
variants in the estrogen receptor can modify the association
between HT and mortality. Some very recent studies have
examined similar polymorphisms and their interactions with HT
in respect to breast cancer risk, but not mortality. Among Hispanic
women, those AA for rs9340799 had an increased risk of breast
cancer with HT compared with women with a G allele who used
HT [33], which supports our findings for cancer-related mortality.
A significant increased risk of breast cancer has also been reported
for women with the genotype GG for rs4986938 or TT for
rs1271572 who had ever used estrogen monotherapy [23]. Such
treatment was used by only a small proportion of women in our
analysis, which may explain the lack of association between these
genotypes and cancer-deaths with HT. There is other evidence in
the literature that estrogen receptor polymorphisms can modulate
the effect of HT on other health outcomes, leading further support
to our findings of an effect on mortality risk. For example
rs2234693 and rs9340799 influence the beneficial effects of HT on
bone mineral density [45] and women with the CC genotype of
rs2234693 showed a greater increase in high-density lipoprotein
cholesterol response with HT compared to other women [24].
ESR2 rs4986938 has also been shown to modulate the decrease in
total cholesterol with HT [25].
Strengths and limitations of the study
Limitations to this study include the 6-year follow-up and small
numberofdeathswhichwas insufficient to examine indetailspecific
causes of mortality such as cardiovascular-related deaths and
specific types of cancer which are likely to be differential associated
withHT(e.g.breast,colorectal).Bias could be introduced duetothe
exclusion of participants with missing data (7%), including a higher
proportion of women who died during follow-up, thus reducing the
power of the study. There is also the possibility of population
stratification which we could not control for because French law
prohibits the collection of data related to ethnicity. Genotype
frequencies forparticipants who died aswell asthosealiveattheend
of follow-up however, were similar to those observed previously in
white Europeans [31,46]. As some of the data such as past HT use,
age at menopause and timing of initiation of HT in relation to the
menopause were collected retrospectively, there may be inaccura-
cies with this data, possibly explaining the lack of significant
associations observed in our analysis. In terms of age at menopause
however, we have previously observed a high level ofreproducibility
between responses at baseline and at the follow-up interviews for a
subset of these participants [47]. Finally, as in all observational
studies, it is possible that there are other factors which were not
considered in this analysis which may have confounded the
associations found in this analysis. Strengths include the sample
size and population-based prospective nature of the study.
Menopausal women had a broad range of health states and patterns
of HT use, thus better reflecting health outcomes in the broader
community. Detailed information on lifetime HT use allowed
specific characteristics of treatment to be examined and compre-
hensive information on the mortality status of the participants was
available. Estrogen receptor polymorphism data enabled genetic
comparisons to be made. Replication of our findings in other large
population-based studies is needed.
Findings from this study indicate for the first time that
polymorphisms of the ESR1 and ESR2 could possibly modify the
association between HT and mortality and this may help explain
previous research inconsistencies. Speculatively this work suggests
that women with certain polymorphisms could benefit from HT in
terms of health-related outcomes, while other women may actually
be genetically more susceptible to the negative effects of HT.
These results require confirmation in another large population-
based study. If they are confirmed they could have important
clinical applications, such as suggesting the clinical utility of
tailoring future prescribing according to genetic vulnerability.
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